Ovarian Cancer Caregivers Have Unique Needs

If metastatic breast cancer no longer responds to a given therapy, finding out what targetable mutations a patient has may guide the next steps for treatment, an expert said.

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.

The Welireg-Cabometyx treatment combination demonstrated anti-tumor activity for some patients with clear cell renal carcinoma, according to a phase 2 trial.

IRON, an artificial intelligence model, has an 80% accuracy rate of predicting therapy outcomes of patients with ovarian cancer.